Crinetics Pharmaceuticals, Inc.
CRNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.56 | -0.46 | -0.65 |
| FCF Yield | -5.56% | -8.28% | -12.28% | -8.15% |
| EV / EBITDA | -11.66 | -9.31 | -5.52 | -8.38 |
| Quality | ||||
| ROIC | -24.52% | -37.38% | -51.58% | -32.15% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.76 | 0.78 | 0.70 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -39.69% | 54.98% | 305.58% | -3.32% |
| Free Cash Flow Growth | -34.40% | -46.32% | -31.27% | -43.10% |
| Safety | ||||
| Net Debt / EBITDA | 0.63 | 0.01 | 0.18 | 1.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,975.51 | 850.51 | 186.85 | 687.00 |